JENTADUETO® (linagliptin/metformin HCl) demonstrates a favourable safety and tolerability profile for a broad range of T2D patients.

The safety of linagliptin 2.5 mg twice daily (or its bioequivalent of 5 mg once daily) in combination with metformin has been evaluated in over 6,800 patients with type 2 diabetes.1

Please see the Summary of Product Characteristics for more information.

In a pooled analysis of seven placebo-controlled trials, the overall incidence of adverse events in patients treated with placebo and metformin was comparable to that seen with linagliptin 2.5 mg and metformin (54.3 and 49.0%).1 Discontinuation of therapy due to adverse events was comparable in patients who received placebo and metformin to patients treated with linagliptin and metformin (3.8% and 2.9%).1

The most frequently reported adverse reaction for linagliptin plus metformin was diarrhoea:1